Radiopharmaceuticals are drugs classified with radioactive compounds typically known as radioisotopes and these drugs are additionally utilized in medical diagnosis as well as therapy of various diseases. Spain radiopharmaceuticals market is growing at a rapid rate due to the increasing number of cancer patients in the country. The increasing prevalence of cardiovascular diseases is fueling the growth of the radiopharmaceuticals market.
The Spain radiopharmaceuticals market is segmented on the basis of radioisotope type, application and end user. The radioisotope type segment is additional categorized into technetium 99m (Tc-99m), fluorine 18 (F-18), Iodine I (I-131), Gallium 68 (Ga-68), and others. Tc-99m is the most extensively utilized radioisotope in radiopharmaceuticals due to its attributes such as easy synthesis and long half-life. The application segment is further sub-segmented into cancer, cardiology, and others. The type segment is categorized into diagnostic and therapeutic. The diagnostic radiopharmaceuticals are utilized to spot the existence of unusual cell growths and is extensively utilized in cancer diagnosis. The therapeutic radiopharmaceuticals segment is anticipated to expand considerably as a result of the increasing number of cancer patients in the nation.
End user segment is classified into hospitals & clinics, clinical imaging facilities, and others. The hospitals segment is the most profitable as a result of the growth of accessibility of advanced radiopharmaceuticals as well as the ever-increasing number of hospital-based procedures.
The increasing number of cancer patients in the country is bringing about high usage of radiopharmaceuticals for medical diagnosis as well as therapy.
The development of radiopharmaceuticals modern technology is expediting the approval of radiopharmaceuticals in the country, which is serving as a major driving factor for Spain radiopharmaceuticals market.
The increasing occurrence of heart diseases is propelling the demand for radiopharmaceuticals in the nation. The high price of radiopharmaceuticals is hindering the growth of the Spain radiopharmaceuticals market. The strict guidelines on the medicine development process are functioning as a restraining variable. The absence of appropriate compensation policies is hindering the development of the radiopharmaceuticals market. The collaborations among radiopharmaceuticals market players and research companies for development is providing a good opportunity for market players. The introduction of new and innovative radiopharmaceuticals are creating investment opportunities for the radiopharmaceuticals players.
The increasing adoption of customized medicine in cancer diagnosis as well as therapy is obtaining traction and is anticipated to be a significant pattern in the development and use of radiopharmaceuticals. The growth of innovative radiopharmaceuticals has made them much more efficient in diagnosis and therapy of various conditions. The development of new radioisotopes such as I-124 as well as Ga-68 which are offering much better imaging attributes than existing ones, is creating new development possibilities in the market.
The rise in cancer, cardiovascular, and neurological illnesses, the rise in demand for medical imaging, and the rise in radiopharmaceutical approvals all contribute to the market growth of radiopharmaceuticals globally. For instance, the FDA of the United States announced the approval of Locametz (active component gallium Ga 68 gozetotide) in March 2022. It is a radioactive diagnostic tool for lesions detected via positron emission tomography that expresses the prostate-specific membrane antigen. Additionally, in March 2022, the pharmaceutical company Novartis announced that Pluvicto had been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC), an advanced cancer. Due to an increase in radiopharmaceutical R&D, the market is growing.
The alarming rise in the incidence of chronic diseases including cancer, cardiovascular diseases, and neurological diseases is a crucial driver propelling the market for radiopharmaceuticals. The need for radiopharmaceuticals is increased by the chronic disease's rising prevalence and the increased demand for diagnosis and therapy. Cancer cells are detected and treated using radioactive medications known as radiopharmaceuticals. They are injected into the body, where they build up in malignant tissues, enabling the identification and treatment of the condition.
To remain affordable, radiopharmaceuticals players ought to focus on offering end-to-end solutions. Mergers and partnerships have come to be the essential approach for radiopharmaceutical players. Radiopharmaceutical manufacturers need to focus on creating new as well as sophisticated radiopharmaceuticals. Market players must concentrate on producing more awareness regarding radiopharmaceuticals.
Radiopharmaceuticals market has been impacted to a great extent as a result of the COVID-19 pandemic. There are now severe shortages of radiopharmaceuticals as a result of the pandemic's impact on production and supply in the nuclear medicine field. Around 81% of the nations reported a decline in diagnostic scintigraphy procedures during the COVID-19 pandemic, according to the European Journal of Nuclear Medicine and Molecular Imaging, published in July 2021.
INSYSBIO, INDUVAC, B-NUCLEAR, GE HEALTHCARE, NUCLEUS BIOTEK, NUCLEON, TRADEO, EGAMMA, PHARMALINE, MEDIPHARMA are some of the companies operating in the market.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in Spain radiopharmaceuticals market.
- Assess and rank the top factors that are expected to affect the growth of Spain radiopharmaceuticals market.
- Top player positioning provides a clear understanding of the present position of market players.
- Detailed analysis of the Spain radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
- Identify key investment pockets for various offerings in the market.
Spain Radiopharmaceuticals Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 77 |
 By Type |
|
 By End User |
|
 By Radioisotope |
|
 By Application |
|
 Key Market Players | B-NUCLEAR, NUCLEUS BIOTEK, INSYSBIO, MEDIPHARMA, EGAMMA, GE HEALTHCARE, NUCLEON, TRADEO, INDUVAC, PHARMALINE |
The Spain Radiopharmaceuticals Market is projected to grow at a CAGR of 9% from 2022 to 2032
Novartis Company, Lantheus, Curium, GE HealthCare, Jubilant Radiopharma, A Jubilant Pharma Company, are the leading players in Spain Radiopharmaceuticals Market
1. Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
2. Analyze the key strategies adopted by major market players in spain radiopharmaceuticals market.
3. Assess and rank the top factors that are expected to affect the growth of spain radiopharmaceuticals market.
4. Top Player positioning provides a clear understanding of the present position of market players.
5. Detailed analysis of the spain radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
6. Identify key investment pockets for various offerings in the market.
Spain Radiopharmaceuticals Market is classified as by end user, by radioisotope, by application, by type
Loading Table Of Content...
Loading Research Methodology...
